Flavocure Biotech Announces FDA Clearance of IND Application for Caflanone (FBL-03G), for Clinical Trials in Pancreatic Cancer Patients.
IND Clearance for a New Class of Therapeutic Prenylated Phenolic FlavonePhase I Clinical Trial Expected to Launch in 2023 and Will Evaluate the Safety and Preliminary Antitumor Activity of Caflanone in combination with radiotherapy.Baltimore, Maryland--(Newsfile Corp. - May 17, 2023) - Flavocure Biotech, Inc. ("Flavocure"), today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase I, first-in-human clinical study of Caflanone (FBL-03G) for the...
2023-05-17 1:00 AM EDT
Flavocure Biotech, Inc. Announces a New Appointment to the Advisory Board
Baltimore, Maryland--(Newsfile Corp. - June 7, 2021) - The Board and Management of Flavocure Biotech, Inc. ("Flavocure") a drug discovery and development company, announced today the appointment of Dr Thomas F. Woolf, PhD, an expert in pharmaceutical sciences to the company's Board of Advisors."Flavocure is a clinical stage ready company, and its first drug candidate targets pancreatic adenocarcinoma which is currently uncurable."Dr Woolf graduated from the University of Washington (Seattle, Washington) with a BS in Pharmacy; University of California...
2021-06-07 2:16 PM EDT
Flavocure Biotech Announces Orphan Designation Granted by FDA for Caflanone (FBL-03G) in Pancreatic Cancer
Baltimore, Maryland--(Newsfile Corp. - October 3, 2019) - Flavocure Biotech, Inc. ("Flavocure") a drug discovery and development company, announced today that the United States Food and Drug Administration (FDA) on September 25, 2019 granted Orphan drug status to its lead drug candidate, Caflanone (FBL-03G) for the treatment of Pancreatic Cancer. "We are very pleased to have received Orphan Drug designation from the FDA for Caflanone. This is a significant milestone that underscores Flavocure's successful innovations and drug development program," said...
2019-10-03 7:38 PM EDT
Flavocure Receives "Green Light" from the United States Patent & Trademark Office and Announces Funding Opportunity
Baltimore, Maryland--(Newsfile Corp. - September 18, 2019) - Flavocure Biotech Inc. ("Flavocure" or the "Company"), a cancer research and drug development company, is pleased to announce that the US Patent and Trademark Office has issued patent No. 10,398,674 for the "Therapeutic Agents Containing Flavonoid Cannabis Derivatives Targeting Kinases, Sirtuins, and Oncologic Agents for the Treatment of Cancers".This proprietary technology is applicable to the treatment of pancreatic related cancers and Flavocure has exclusive rights to the patented technology. Discovered...
2019-09-18 9:00 AM EDT
Flavocure Pancreatic Drug Discovery Attracts Major Asian Equity Investor
Baltimore, Maryland--(Newsfile Corp. - April 9, 2019) - Dr. Henry Lowe, the executive Chairman of Flavocure Biotech Inc, today announced that Denning Growth Fund ("DGF") has invested $1.5 million USD in Flavocure Biotech, Inc. a disruptive innovator in oncological drug discovery. DGF, which is controlled by one of Asia's richest tycoons, has added Flavocure to their life sciences portfolio. Dr. Henry Lowe stated, "The potential efficacy of Flavocure's drug has been validated in a large cohort study completed...
2019-04-09 12:19 PM EDT
Flavocure Biotech, Inc. Announces Special Appointments to the Advisory Board and Regulatory Affairs
Baltimore, Maryland--(Newsfile Corp. - February 25, 2019) - Dr. Henry Lowe Ph.D. announces - It is with pleasure that Flavocure Biotech, Inc. welcomes the creation of Advisory Board Chairman, reporting to the company's board of directors. In the creation of this new role, Dr. Jose Luis Calderon, M.D. has accepted the role as Chairman of the Advisory Board of Directors. Dr. Calderon, a graduate of Harvard Medical School, also serves as a member of the Division of General...
2019-02-25 10:00 AM EST
Flavocure Announces Initiation of IND Enabling Studies for Drug to Treat Pancreatic and Glioblastoma Cancers
Baltimore, Maryland--(Newsfile Corp. - January 16, 2019) - Flavocure Biotech, Inc., announced today that it has initiated Investigational New Drug (IND) enabling studies for its cannabis derived drug, FBL-03G. The studies, which are estimated to cost over $1 million, have been independently sponsored by the company's Executive Vice Chairman, Clark Swanson. The commitment paves the way for Flavocure to attain IND status from the FDA. The effort is expected to be completed within 9 - 12 months,...
2019-01-16 9:00 AM EST